Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
in vivo CD19-targeted CAR-T mRNA-LNP therapy
- Development stage
- Phase 1
- Lead developer
- Xinqiao Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular
01
Overview
This experimental therapy represents an in vivo approach to chimeric antigen receptor (CAR) T-cell therapy, developed by Xinqiao Hospital of Chongqing. It utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding an anti-CD19 CAR directly into the patient's body via intravenous or intramuscular injection. Unlike conventional CAR-T therapies that require complex ex vivo cell engineering (harvesting, modifying, and re-infusing a patient's cells), this method aims to reprogram the patient's own T cells within the body to transiently express the CAR. The resulting CAR-T cells target and deplete CD19-positive B cells, which are central to the pathogenesis of various refractory autoimmune diseases. This 'off-the-shelf' approach potentially simplifies the manufacturing process and reduces the time to treatment compared to traditional cell therapies.
- Other names
- in vivo CAR-T drug based on LNP-mRNAmRNA Therapy Targeting CD19
02
Targets
Beyond the preview
Go deeper on in vivo CD19-targeted CAR-T mRNA-LNP therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on in vivo CD19-targeted CAR-T mRNA-LNP therapy.